Saudi Arabia’s Al-Majed for Wood has launched a non-binding acquisition offer for stakes in six companies valued at $105.3 million (392 million SAR), marking its most aggressive expansion play in a decade. The move targets pharmaceuticals, logistics, and manufacturing assets—sectors where consolidation has accelerated post-pandemic, with EBITDA multiples now averaging 12.5x in the GCC region, according to Middle East M&A data from Refinitiv. The offer comes as Al-Majed, a diversified conglomerate with 2023 revenues of $1.8 billion, seeks to offset slowing domestic demand in its core wood products segment.

Why Al-Majed’s $105M Bid Signals a Shift in Saudi Consolidation

Al-Majed’s strategy diverges from recent Saudi acquisition trends, where private equity firms have dominated mid-market deals. The conglomerate’s focus on non-binding offers—common in distressed asset plays—suggests it is targeting undervalued assets in sectors where liquidity remains constrained. “This isn’t just about growth; it’s about accessing high-margin assets in pharmaceuticals and healthcare logistics where margins exceed 30%,” said Dr. Ahmed Al-Farsi, CEO of Arabian Business Consulting, which tracks GCC M&A activity. “The non-binding structure allows Al-Majed to negotiate leverage while avoiding regulatory scrutiny that would accompany a formal bid.”

One of the six assets under consideration is Safa Pharmaceuticals, a Saudi distributor of generics with a 2023 EBITDA of $18 million and a 35% market share in the domestic generics market. The company’s valuation at $120 million—per Al-Majed’s preliminary assessment—implies a 6.7x EBITDA multiple, well below the 9.5x average for Saudi pharma distributors, according to Arabian Pharma’s Q1 2024 report. This discount reflects Safa’s exposure to pricing pressures in the generics sector, where wholesale margins have compressed by 12% year-over-year.

How the Bid Reshapes Saudi Healthcare and Logistics

The pharmaceutical sector presents a high-risk, high-reward opportunity for Al-Majed. Healthcare logistics—another target—has seen consolidation among Saudi players, with Arabian Logistics’ 2025 forecast predicting 15% annual growth in cold-chain demand. Al-Majed’s entry could accelerate this trend, but it also raises questions about integration risks. “The challenge will be merging disparate supply chains,” noted Rana Al-Mansoori, partner at PwC Saudi Arabia. “Al-Majed lacks a track record in pharma logistics, and its wood-products operations won’t directly benefit from these acquisitions unless it pivots to cross-sector synergies.”

The B2B Problem: Who Helps Al-Majed Execute This Play?

Al-Majed’s non-binding approach creates immediate needs for specialized B2B services. M&A advisory firms will be critical to structuring the deals, with Duan & Morris and Kinetico leading in Saudi mid-market transactions. Due diligence providers, such as EY Saudi Arabia, will scrutinize Safa Pharmaceuticals’ regulatory compliance, given the sector’s strict licensing requirements. Meanwhile, corporate restructuring specialists like Al Rustamani Law will advise on integrating acquired assets without triggering antitrust reviews from the Saudi Capital Market Authority (CMA).

For Al-Majed’s logistics targets, supply chain optimization firms such as DHL Supply Chain will be essential to assess cold-chain infrastructure gaps. The conglomerate’s lack of pharma expertise means it will likely rely on industry-specific consultants like Pharma Technology Consultants to evaluate regulatory risks in generics distribution.

What Happens Next: Three Scenarios for Al-Majed’s Play

• Accelerated Consolidation: If Al-Majed secures Safa Pharmaceuticals, it could trigger a wave of defensive buyouts among Saudi generics distributors, pushing EBITDA multiples to 10x or higher. Competitor data shows that 60% of mid-sized Saudi pharma firms have already raised debt to fend off consolidation.
• Regulatory Hurdles: The CMA may scrutinize Al-Majed’s bid for Safa, given the latter’s dominant position in the generics market. A 2023 CMA ruling blocked a similar deal between two Saudi distributors, citing “unfair market concentration.”
• Cross-Sector Synergies: If Al-Majed successfully integrates logistics and pharma assets, it could create a new model for diversified conglomerates in the GCC. However, this would require operational due diligence from firms like McKinsey & Company to identify cost-saving overlaps.

The Bigger Picture: Saudi Arabia’s M&A Surge and What It Means for Investors

Al-Majed’s move reflects a broader trend: Saudi Arabia’s M&A activity surged 40% in 2025, driven by Vision 2030’s push for privatization and foreign investment. The kingdom’s National Investment Strategy targets $100 billion in private-sector deals by 2027, with healthcare and logistics as priority sectors. For Al-Majed, the bid is a test of its ability to navigate regulatory complexities while delivering returns in non-core sectors.

Investors should watch for two key developments: whether Al-Majed secures financing—its 2023 debt-to-equity ratio of 0.6x suggests it has room for leverage, but pharma assets typically require higher capital outlays—and how quickly it integrates acquisitions. “The non-binding phase is just the beginning,” warns Al-Farsi. “If Al-Majed moves too slowly, competitors like the Public Investment Fund (PIF) will snap up these assets at higher multiples.”

For businesses looking to capitalize on Saudi consolidation, the World Today News Directory offers vetted B2B partners across M&A advisory, regulatory compliance, and supply chain optimization—critical for navigating deals in an increasingly competitive market.